In addition to therapy targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) which is being used in the treatment of a number of malignancies including HGUC[7–12], cancer vaccines are another immunotherapy treatment strategy which is being studied in a number of tumour types. The gene discussed is PDCD1; the disease is neoplasm.